ADRX Stock Forecast: ADARx Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 29 Sept 2026 — in the weakest quartile.
ADRX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores ADARx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (38): Smaller than most of the companies we track.
Volatility (1): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ADRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ADRX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADRX appears on the weeks it earns a place.
ADRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
ADARx Pharmaceuticals, Inc. (ADRX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- −19.8×
- Revenue growth (YoY)
- 258.7%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −4006.8%
- Net margin
- 0.0%
- Return on equity
- —
- Return on assets
- —
- Dividend yield
- —
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ADARx Pharmaceuticals, Inc. (ADRX) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ADARx Pharmaceuticals, Inc. has a market value of $0.0 and an enterprise value of $2.1B.
ADARx Pharmaceuticals, Inc. employs 0 people.
Data provided by Twelve Data
ADRX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ADARx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ADRX stock
How does Ticker Nerd's model rank ADRX?
As at 29 Sept 2026, ADARx Pharmaceuticals, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (38 of 100).
What is the ADRX stock forecast for 2030?
No analyst covering ADARx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADRX are extrapolating price history, which says nothing about the business.
What does ADARx Pharmaceuticals, Inc. do?
ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing next-generation siRNA therapeutics.
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing next-generation siRNA therapeutics. The company works on RNA interference-based medicines designed to silence disease-causing genes and address conditions with significant unmet medical needs. Its current pipeline includes hepatic-targeted programs such as Agazisiran, a complement factor B program, Onvuzosiran for hereditary angioedema attack prevention, and ADX-626, a Factor XI program being studied for thrombotic disease and stroke prevention applications. ADARx Pharmaceuticals operates in the broader genetic medicine and precision therapeutics markets, where it aims to translate advanced oligonucleotide science into targeted treatments across multiple disease areas. Based in San Diego, California, the company is positioned as a clinical biotechnology developer with a focus on translational research and specialty drug development.
CEO Dr. Zhen Li Ph.D. · United States · https://www.adarx.com